⏎ Words Summary from News
**Chen Weiqiang, a former tenured professor at New York University and pioneer of 'cancer-on-a-chip' technology, has returned to China to join Nanjing University as a distinguished professor.** The move was formalized with a welcome ceremony at Nanjing University's Suzhou campus on June 11, after Chen completed his work at NYU in May. He cited personal career development and family reasons for the decision, explicitly stating he did not consider political changes in the United States.</p><p class="summary-lead">**Chen developed a groundbreaking 'cancer-on-a-chip' method that mimics a patient's specific tissue environment using their own cells, allowing for targeted treatment testing.** This technology offers a simple way to study aggressive cancers under normal human body conditions and provides a window into future cancer therapies. His work earned him an American Heart Association fellowship in 2023 and promotion to full tenured professor at NYU in March 2024.</p><p class="summary-lead">**The return of a top-tier researcher at his peak academic years signals China's aggressive push to reclaim talent from Western institutions.** Nanjing University, which ranks ninth globally in the 2026 Nature Index versus NYU's 72nd, established its biomedical engineering school in December to focus on life sciences and clinical needs. Chen has pledged to deepen his research, nurture talent, and promote industry-academia integration to meet the school's high expectations.</p><p class="summary-lead">**This repatriation trend has strategic implications for global biomedical innovation, as China gains expertise in cutting-edge organ-chip and cellular biomechanics fields.** Chen's nearly 70 peer-reviewed articles and leadership of projects totaling over 63 million yuan underscore the scale of expertise now shifting eastward. The move may accelerate China's development of alternative animal testing methods, given Chen's role in founding the world's first data research center for novel animal alternative methods at NYU.</p><p class="summary-lead">**What to watch next:** Whether more top-tier U.S.-based Chinese researchers follow Chen's path, and how his cancer-on-a-chip technology translates into clinical applications within China's rapidly expanding biomedical infrastructure.
Key Takeaways
- Chen Weiqiang left a tenured NYU position to join Nanjing University, citing personal and family reasons, not U.S. political changes.
- His 'cancer-on-a-chip' technology enables personalized treatment testing using a patient's own cells in a lab environment.
- Nanjing University ranks 9th globally in the 2026 Nature Index, far ahead of NYU's 72nd place, reflecting China's rising research power.
- Chen's return aligns with China's strategic effort to attract top scientific talent to bolster its biomedical engineering sector.
Insights & Analysis
- This move may trigger a broader brain drain from U.S. institutions to China, especially in high-impact biomedical fields where China is investing heavily.
- Chen's expertise in organ-chip technology could give China a competitive edge in reducing reliance on animal testing and accelerating drug development timelines.